

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING	DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/849,039	05/20	0/2004	James T. Dalton	P-5235-US14	7024
49443	7590	07/11/2006		EXAMINER	
	HEN ZEDE	•	KUMAR, SHAILENDRA		
1500 BROADWAY 12TH FLOOR NEW YORK, NY 10036			ART UNIT	PAPER NUMBER	
				1621 DATE MAILED: 07/11/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
•		10/849,039	DALTON ET AL.			
Office Action Summary		Examiner	Art Unit			
		SHAILENDRA KUMAR	1621			
- The MAILING DATE of this communication appears on the cover sheet with the correspondence address - Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠	Responsive to communication(s) filed on 26 Ag	<u>oril 2006</u> .				
,—	This action is FINAL . 2b)⊠ This action is non-final.					
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims					
5)□ 6)⊠ 7)□	Claim(s) 1-95 is/are pending in the application. 4a) Of the above claim(s) 21-23,32-34,38-51,65 Claim(s) is/are allowed. Claim(s) 1-20,24-31,35-37,52-64,68-75 and 79 Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	5 <u>-67,76-78 <i>and 82</i>-95</u> is/are withd 1 <u>-81</u> is/are rejected.	rawn from consideration.			
Application Papers						
10)	The specification is objected to by the Examiner The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction The oath or declaration is objected to by the Ex	epted or b) objected to by the Eddrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).			
Priority u	nder 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment		_				
2) Notice (3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:				

Art Unit: 1621

DETAILED ACTION

This office action is in response to applicants' communication filed on 4/26/06.

Claims 1-95 are pending in this application.

At the out set, claims 21-23 and 32 should be withdrawn as containing O-glucoronide containing group. See, restriction requirement of 8/15/05. Inclusion of claims 21-23 and 32 in Group I was an inadvertent error and is regretted. Thus elected claims are 1-20, 24-31, 35-37, 52-64, 68-75 and 79-81. Claims 22-23, 32-34, 38-51, 65-67, 76-78 and 82-95 stand withdrawn as none elected invention.

Rejection of claims 63, 69-75 and 79-81 under 35 USC 112 2nd paragraph is hereby withdrawn, subsequent to applicants' arguments.

Rejection of various claims under 35 USC 103 over Miller et al is hereby withdrawn subsequent to applicants' submission of a statement claiming common ownership.

Claim Rejections - 35 USC § 103

1. Claims 1-20, 24-31, 35-37, 52-64, 68-75 and 79-81 are rejected under 35 U.S.C. 103(a) as being unpatentable over combined teachings of WO 98/55153 and Tucker et al.

Instant claims are directed to anilide derivatives as metabolites wherein, Q can be among others, F or acetamido.

WO'153 teach structurally similar compounds and composition which are radiolabeled. See pages 6-7, wherein, R7 can be phenyl substituted with amino, F or alkylamido. The difference between the reference and herein claimed compounds and

composition is that the reference compounds are radiolabeled as against non radiolabeled compounds claimed herein.

Tucker et al are teaching structurally similar compounds and composition which are non radiolabeled, see column 1 through column 3.

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to modify WO'153 and obtain non radiolabeled compounds and composition, as taught by Tucker et al, because the latter reference is expressly teaching that structurally similar compounds and composition can be non radiolabeled.

Applicants' arguments that Tucker does not teach metabolites, is of little if any probative value inasmuch as the compounds are structurally similar and the property of these compounds to be metabolite in inherent, absent evidence to the contrary.

Double Patenting

2. Claims 1-20, 24-31, 35-37, 52-64, 68-75 and 79-81 are again rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-85 of U.S. Patent No. 6,838,484, or over claims 1-10 of U.S. Patent No. 6,569,896, or over claims 1-5 of U.S. Patent No. 6,492,554, all for the reasons of record. Although the conflicting claims are not identical, they are not patentably distinct from each other because various substituents as claimed herein extensively overlap those in the above patents, and one of ordinary skill in the ad would have obtained compounds within the generic disclosure of the above patents, because they are structurally so similar to those claimed herein, with the reasonable expectation of achieving a successful composition, absent evidence to the contrary.

Application/Control Number: 10/849,039 Page 4

Art Unit: 1621

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHAILENDRA -. KUMAR whose telephone number is (571)272-0640. The examiner can normally be reached on Mon-Thur 8:00-5:30, Alt Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on (571)272-0602. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

SHAILENDRA - KUMAR Primary Examiner

Art Unit 1621

S.Kumar 6/30/06